Multisystem inflammatory syndrome in a young infant with lymphocytosis and reactive thrombocytosis post COVID-19: Case report
Main Article Content
Keywords
COVID-19, Infant Health, Thrombocytosis, Lymphocytosis, Mucocutaneous Lymph Node Syndrome
Abstract
Background: Multisystem inflammatory syndrome in children (MIS-C) is a rare, but serious complication associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, characterized by persistent fever, systemic inflammation, and multiorgan involvement. It predominantly affects school-aged children and adolescents. Reports in infants under 1 year are limited, and atypical presentations pose diagnostic challenges.
Clinical case: 8-month-old male infant who presented with 10 days of persistent fever, diarrhea, and irritability. Initial laboratory findings revealed leukocytosis, marked thrombocytosis, persistent lymphocytosis, and significantly elevated liver enzymes. No mucocutaneous findings or cardiac involvement were noted. The diagnosis of MIS-C was established based on Centers for Disease Control and Prevention (CDC) criteria and confirmed by positive IgG serology for SARS-CoV-2. Treatment with intravenous immunoglobulin (IVIg), aspirin, and corticosteroids achieved a favorable clinical and biochemical evolution.
Conclusions: This case highlights an atypical presentation of MIS-C in a young infant, with hematological findings that differ from classic patterns. Early recognition and standard immunomodulatory therapy led to a successful outcome. Documenting such variants is essential to expand our understanding of MIS-C in underrepresented age groups.
References
1. Centers for Disease Control and Prevention. Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19) [Internet]. 2020 [citado el 1 de julio de 2025]. Disponible en: https://emergency.cdc.gov/han/2020/han00432.asp
2. World Health Organization. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19 [Internet]. 2020 [citado el 1 de julio de 2025]. Disponible en: https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19
3. European Centre for Disease Prevention and Control. Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children [Internet]. 2020 [citado el 1 de julio de 2025]. Disponible en: https://www.ecdc.europa.eu/en/publications-data/paediatric-inflammatory-multisystem-syndrome-and-sars-cov-2-infection-children
4. Kabeerdoss J, Pilania RK, Karkhele R, et al. Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: immunological mechanisms, clinical manifestations and management. Rheumatol Int. 2021;41(1):19-32. doi: 10.1007/s00296-020-04749-4
5. Sharma C, Ganigara M, Galeotti C, et al. Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison. Nat Rev Rheumatol. 2021;17(12):731-48. doi: 10.1038/s41584-021-00709-9
6. Bojan A, Parvu A, Zsoldos IA, et al. Macrophage activation syndrome: A diagnostic challenge (Review). Exp Ther Med [Internet]. 2021;22(2):904. doi: 10.3892/etm.2021.10336
7. Mercado Uribe M, Martínez Arce PA, Guerrero Becerra M. Síndrome multisistémico inflamatorio en niños (MIS-C) posiblemente asociado a vacuna COVID-19 Pfizer-BioNTech mRNA (BNT162b2). Reporte de caso. Acta Pediatr Mex. 2025;46(2):204-11. doi: 10.18233/apm.v46i2.2738
8. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020;383(4):334-46. doi: 10.1056/NEJMoa2021680
9. Patel A, Agarwal R, Rudramurthy SM, et al. Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India. Emerg Infect Dis. 2021;27(9):2349-59. doi: 10.1007/s11882-022-01031-4
10. Carter MJ, Fish M, Jennings A, et al. Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. Nat Med. 2020;26(11):1701-7. doi: 10.1038/s41591-020-1054-6
11. Barroso-Santos J, Robledo-Martínez AI, Espinosa-Padilla SE, et al. Multisystemic Inflammatory Syndrome Temporally Associated with COVID-19 in a Regional Pediatric Hospital from México. Pediatr Rep. 2023;15(2):341-8. doi: 10.3390/pediatric15020030
12. Pessoa FS, Lacerda EM da CB, Gonçalves VC, et al. Case Report: MIS-C Temporarily Associated With COVID-19 Complicated by Reye’s Syndrome. Front Pediatr. 2021;9:650697. doi: 10.3389/fped.2021.650697
13. Tong T, Yao X, Lin Z, et al. Similarities and differences between MIS-C and KD: a systematic review and meta-analysis. Pediatric Rheumatology. 2022;20(1):112. doi: 10.1186/s12969-022-00771-x
14. Saha S, Pal P, Mukherjee D. Neonatal MIS-C: Managing the Cytokine Storm. Pediatrics. 2021;148(5):e2020042093. doi: 10.1542/peds.2020-042093
15. Rokkam VR, Killeen RB, Kotagiri R. Secondary Thrombocytosis. En: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [citado el 1 de julio de 2025]. Disponible en: http://www.ncbi.nlm.nih.gov/books/NBK560810/
16. Whittaker E, Bamford A, Kenny J, et al. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. JAMA. 2020;324(3):259-69. doi: 10.1001/jama.2020.10369
17. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A scientific statement for health professionals from the American Heart Association. Circulation [Internet]. 2017;135(17):e927-99. doi: 10.1161/CIR.0000000000000484
18. Giraldo-Alzate C, Tamayo-Múnera C, López-Barón E, et al. Síndrome inflamatorio multisistémico en niños asociado a COVID-19. Revisión narrativa de la literatura a propósito de un caso. Acta Colombiana de Cuidado Intensivo. 2022;22(2):137-48. doi: 10.1016/j.acci.2020.11.002
19. Otar Yener G, Paç Kısaarslan A, Ulu K, et al. Differences and similarities of multisystem inflammatory syndrome in children, Kawasaki disease and macrophage activating syndrome due to systemic juvenile idiopathic arthritis: a comparative study. Rheumatol Int. 2022;42(5):879-89. doi: 10.1007/s00296-021-04980-7
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.